AbbVie Inc (ABBV)vsIradimed Co (IRMD)
ABBV
AbbVie Inc
$203.89
+3.64%
HEALTHCARE · Cap: $360.63B
IRMD
Iradimed Co
$83.44
-0.32%
HEALTHCARE · Cap: $1.07B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 72871% more annual revenue ($61.16B vs $83.81M). IRMD leads profitability with a 26.8% profit margin vs 6.9%. ABBV appears more attractively valued with a PEG of 0.48. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
IRMD
Buy60
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$203.89
$40.47 premium
Margin of Safety
-81.7%
Fair Value
$56.73
Current Price
$83.44
$26.71 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Strong operational efficiency at 31.3%
Every $100 of equity generates 25 in profit
Keeps 27 of every $100 in revenue as profit
17.0% revenue growth
Earnings expanding 24.8% YoY
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
Trading at 11.3x book value
Smaller company, higher risk/reward
Expensive relative to growth rate
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : IRMD
The strongest argument for IRMD centers on Operating Margin, Return on Equity, Profit Margin. Profitability is solid with margins at 26.8% and operating margin at 31.3%. Revenue growth of 17.0% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : IRMD
The primary concerns for IRMD are Price/Book, Market Cap, PEG Ratio. A P/E of 47.8x leaves little room for execution misses.
Key Dynamics to Monitor
ABBV profiles as a value stock while IRMD is a growth play — different risk/reward profiles.
IRMD carries more volatility with a beta of 1.12 — expect wider price swings.
IRMD is growing revenue faster at 17.0% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 60/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Iradimed Co
HEALTHCARE · MEDICAL DEVICES · USA
IRADIMED CORPORATION develops, manufactures, markets and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories and services in the United States and internationally. The company is headquartered in Winter Springs, Florida.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?